Glycyl-L-Prolyl-L-Glutamate Pseudotripeptides for Treatment of Alzheimer’s Disease

Glycyl-L-Prolyl-L-Glutamate Pseudotripeptides for Treatment of Alzheimer’s Disease

So far, there is no effective disease-modifying therapies for Alzheimer’s Disease (AD) in clinical practice. In this context, glycine-L-proline-L-glutamate (GPE) and its analogs may open the way for developing a novel molecule for treating neurodegenerative disorders, including AD. In turn, this stu...

Full description

Bibliographic Details
Main Authors: Hasan Turkez, Ivana Cacciatore, Lisa Marinelli, Erika Fornasari, Mehmet Enes Aslan, Kenan Cadirci, Cigdem Yuce Kahraman, Ozge Caglar, Abdulgani Tatar, Giuseppe Di Biase, Ahmet Hacimuftuoglu, Antonio Di Stefano, Adil Mardinoglu
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Biomolecules
Subjects:
Alzheimer’s disease
neurotoxicity
glycine-proline-glutamate peptidomimetics
in vitro cell culture model
gene expressions
Online Access:https://www.mdpi.com/2218-273X/11/1/126

Internet

https://www.mdpi.com/2218-273X/11/1/126

Similar Items